The Independent Director of AlzeCure Pharma AB (publ) (STO:ALZCUR), Ragnar Linder, Just Bought 195% More Shares
Even if it's not a huge purchase, we think it was good to see that Ragnar Linder, the Independent Director of AlzeCure Pharma AB (publ) (STO:ALZCUR) recently shelled out kr56k to buy stock, at kr5.30 per share. Even though that isn't a massive buy, it did increase their holding by 195%, which is a arguably a good sign.
View our latest analysis for AlzeCure Pharma
The Last 12 Months Of Insider Transactions At AlzeCure Pharma
In fact, the recent purchase by Ragnar Linder was the biggest purchase of AlzeCure Pharma shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of kr5.50 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. Happily, the AlzeCure Pharma insider decided to buy shares at close to current prices. Ragnar Linder was the only individual insider to buy shares in the last twelve months.
The chart below shows insider transactions (by individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Does AlzeCure Pharma Boast High Insider Ownership?
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 17% of AlzeCure Pharma shares, worth about kr35m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Does This Data Suggest About AlzeCure Pharma Insiders?
It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of AlzeCure Pharma we think they are probably pretty confident of a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 5 warning signs we've spotted with AlzeCure Pharma (including 2 which are a bit unpleasant).
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.
